As TGF-β is commonly expressed in NY-ESO-1+ cancers (53), the combination of TCR-like CAR-T cells targeting NY-ESO-1/HLA (18) with TGF-β blockade could be applicable for NY-ESO-1+ hematological malignancies as well. This evidence concerns the gene TGFB1 and hematologic disorder.